BACKGROUND: In January 2008, the Centers for Disease Control and Prevention began a nationwide investigation of severe adverse reactions that were first detected in a single hemodialysis facility. Preliminary findings suggested that heparin was a possible cause of the reactions. METHODS: Information on clinical manifestations and on exposure was collected for patients who had signs and symptoms that were consistent with an allergic-type reaction after November 1, 2007. Twenty-one dialysis facilities that reported reactions and 23 facilities that reported no reactions were included in a case-control study to identify facility-level risk factors. Unopened heparin vials from facilities that reported reactions were tested for contaminants. RESULTS: A total of 152 adverse reactions associated with heparin were identified in 113 patients from 13 states from November 19, 2007, through January 31, 2008. The use of heparin manufactured by Baxter Healthcare was the factor most strongly associated with reactions (present in 100.0% of case facilities vs. 4.3% of control facilities, P<0.001). Vials of heparin manufactured by Baxter from facilities that reported reactions contained a contaminant identified as oversulfated chondroitin sulfate (OSCS). Adverse reactions to the OSCS-contaminated heparin were often characterized by hypotension, nausea, and shortness of breath occurring within 30 minutes after administration. Of 130 reactions for which information on the heparin lot was available, 128 (98.5%) occurred in a facility that had OSCS-contaminated heparin on the premises. Of 54 reactions for which the lot number of administered heparin was known, 52 (96.3%) occurred after the administration of OSCS-contaminated heparin. CONCLUSIONS: Heparin contaminated with OSCS was epidemiologically linked to adverse reactions in this nationwide outbreak. The reported clinical features of many of the cases further support the conclusion that contamination of heparin with OSCS was the cause of the outbreak. 2008 Massachusetts Medical Society
BACKGROUND: In January 2008, the Centers for Disease Control and Prevention began a nationwide investigation of severe adverse reactions that were first detected in a single hemodialysis facility. Preliminary findings suggested that heparin was a possible cause of the reactions. METHODS: Information on clinical manifestations and on exposure was collected for patients who had signs and symptoms that were consistent with an allergic-type reaction after November 1, 2007. Twenty-one dialysis facilities that reported reactions and 23 facilities that reported no reactions were included in a case-control study to identify facility-level risk factors. Unopened heparin vials from facilities that reported reactions were tested for contaminants. RESULTS: A total of 152 adverse reactions associated with heparin were identified in 113 patients from 13 states from November 19, 2007, through January 31, 2008. The use of heparin manufactured by Baxter Healthcare was the factor most strongly associated with reactions (present in 100.0% of case facilities vs. 4.3% of control facilities, P<0.001). Vials of heparin manufactured by Baxter from facilities that reported reactions contained a contaminant identified as oversulfated chondroitin sulfate (OSCS). Adverse reactions to the OSCS-contaminated heparin were often characterized by hypotension, nausea, and shortness of breath occurring within 30 minutes after administration. Of 130 reactions for which information on the heparin lot was available, 128 (98.5%) occurred in a facility that had OSCS-contaminated heparin on the premises. Of 54 reactions for which the lot number of administered heparin was known, 52 (96.3%) occurred after the administration of OSCS-contaminated heparin. CONCLUSIONS:Heparin contaminated with OSCS was epidemiologically linked to adverse reactions in this nationwide outbreak. The reported clinical features of many of the cases further support the conclusion that contamination of heparin with OSCS was the cause of the outbreak. 2008 Massachusetts Medical Society
Authors: M Beatriz Souza Dias; Alina Bernardes Habert; Vera Borrasca; Valeska Stempliuk; Aina Ciolli; M Rita E Araújo; Silvia F Costa; Anna S Levin Journal: Infect Control Hosp Epidemiol Date: 2008-02 Impact factor: 3.254
Authors: Takashi Kei Kishimoto; Karthik Viswanathan; Tanmoy Ganguly; Subbiah Elankumaran; Sean Smith; Kevin Pelzer; Jonathan C Lansing; Nammalwar Sriranganathan; Ganlin Zhao; Zoya Galcheva-Gargova; Ali Al-Hakim; Gregory Scott Bailey; Blair Fraser; Sucharita Roy; Thomas Rogers-Cotrone; Lucinda Buhse; Mark Whary; James Fox; Moheb Nasr; Gerald J Dal Pan; Zachary Shriver; Robert S Langer; Ganesh Venkataraman; K Frank Austen; Janet Woodcock; Ram Sasisekharan Journal: N Engl J Med Date: 2008-04-23 Impact factor: 91.245
Authors: Jing Pan; Yi Qian; Xiaodong Zhou; Andrew Pazandak; Sarah B Frazier; Peter Weiser; Hong Lu; Lijuan Zhang Journal: Nat Biotechnol Date: 2010-03 Impact factor: 54.908
Authors: Bianca F Glauser; Ricardo M Rezende; Fabio R Melo; Mariana S Pereira; Ivo M B Francischetti; Robson Q Monteiro; Alireza R Rezaie; Paulo A S Mourão Journal: Thromb Haemost Date: 2009-12 Impact factor: 5.249